TY - JOUR
T1 - The safety of biological pharmacotherapy for the treatment of ulcerative colitis
AU - Fiorino, Gionata
AU - Bonovas, Stefanos
AU - Cicerone, Clelia
AU - Allocca, Mariangela
AU - Furfaro, Federica
AU - Correale, Carmen
AU - Danese, Silvio
AU - Danese, Silvio
PY - 2017/4/3
Y1 - 2017/4/3
N2 - © 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Biological agents are effective in ulcerative colitis (UC). Currently, 3 anti-TNF agents (infliximab, adalimumab, and golimumab) and 1 anti-integrin agent (vedolizumab) are approved for the treatment of UC. The mechanism of action of biologic agents can also give rise to several side effects, some even serious. It remains uncertain to what extent biologic treatments may be associated with an increased rate of infections, malignancies and other adverse events Areas covered: Our aim is to review the relevant data available in the literature and briefly summarize the safety profile of biological therapy in UC. We performed a literature search using the OVID, MEDLINE, PUBMED and EMBASE databases. Also other relevant sources of safety data were also used. Expert opinion: All biological agents currently used in UC are relatively safe. Accurate prevention measures and screening pri or to start such therapies, and regular surveillance programs are strongly recommend to minimize any risk of infections, malignancy and other adverse events related to the use of monoclonal antibodies in UC patients.
AB - © 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Biological agents are effective in ulcerative colitis (UC). Currently, 3 anti-TNF agents (infliximab, adalimumab, and golimumab) and 1 anti-integrin agent (vedolizumab) are approved for the treatment of UC. The mechanism of action of biologic agents can also give rise to several side effects, some even serious. It remains uncertain to what extent biologic treatments may be associated with an increased rate of infections, malignancies and other adverse events Areas covered: Our aim is to review the relevant data available in the literature and briefly summarize the safety profile of biological therapy in UC. We performed a literature search using the OVID, MEDLINE, PUBMED and EMBASE databases. Also other relevant sources of safety data were also used. Expert opinion: All biological agents currently used in UC are relatively safe. Accurate prevention measures and screening pri or to start such therapies, and regular surveillance programs are strongly recommend to minimize any risk of infections, malignancy and other adverse events related to the use of monoclonal antibodies in UC patients.
KW - adalimumab
KW - golimumab
KW - Infliximab
KW - safety
KW - ulcerative colitis
KW - vedolizumab
UR - http://www.scopus.com/inward/record.url?scp=85015987518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015987518&partnerID=8YFLogxK
U2 - 10.1080/14740338.2017.1298743
DO - 10.1080/14740338.2017.1298743
M3 - Review article
C2 - 28279079
AN - SCOPUS:85015987518
VL - 16
SP - 437
EP - 443
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 4
ER -